Study guide
Screening, Early Detection, and High-Risk Referrals
OCN Oncology Certified Nurse Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: OCN Exam Orientation and Official Source Control
Official Sources and Credential Purpose Eligibility, Application, and Fees Exam Format, Scoring, Blueprint, and Generic Drugs PSI Scheduling, ATT, Test Day, and Results Blueprint-Based Study Plan and Readiness
2 Chapter 2: Care Continuum, Prevention, Survivorship, and End-of-Life Care
Health Promotion, Risk Reduction, and Epidemiology Screening, Early Detection, and High-Risk Referrals Navigation, Coordination, and Care Continuity Palliative Care, Advance Care Planning, and Goals Survivorship, Rehabilitation, Recurrence, and Late Effects Sexuality, Family Support, Discrimination, and Social Needs End-of-Life Care, Hospice, Bereavement, and Comfort Measures
3 Chapter 3: Oncology Science and Site-Specific Cancer Assessment
Carcinogenesis, Immunology, and Cancer Biology Genomic, Genetic Testing, and Biomarker Literacy Clinical Trials, Research Protocols, and Informed Participation Diagnostic Workup, Biopsy, Imaging, and Pathology Basics Staging, Grading, Prognosis, and Performance Status Common Cancer Patterns and Metastatic Sites Oncology Assessment, Data Clustering, and Escalation
4 Chapter 4: Professional Oncology Nursing Practice, Safety, and Standards
Scope, Standards, Nursing Process, and Documentation Collaboration, Communication, and Interprofessional Practice Safe Handling, PPE, Occupational Health, and Exposure Response Culturally Congruent Care, Advocacy, and Ethics Self-Care, Compassion Fatigue, Burnout, and Professional Development
5 Chapter 5: Treatment Modalities I - Surgery, Radiation, Transplant, Localized and Oral Therapy
Surgery and Procedural Oncology Nursing Care Radiation Therapy Principles, Toxicities, and Teaching Blood and Marrow Transplant Foundations Localized Therapy: Intrathecal, Intravesical, and Regional Care Oral Oncology Therapy Adherence, Safety, and Education Treatment Sequencing, Response Monitoring, and Care Coordination Modality-Specific Patient Teaching and Documentation
6 Chapter 6: Treatment Modalities II - Systemic Therapy, Immunotherapy, and Targeted Agents
Chemotherapy Foundations and Infusion Safety Biotherapy, Immunotherapy, and Immune-Related Adverse Events Targeted Therapy, Immune Cell, and Bispecific Antibody Basics Hormonal Therapy and Endocrine Cancer Treatment Considerations Vascular Access, Infusion Monitoring, and Extravasation Prevention Systemic Therapy Patient Education and Home Safety Therapy Response, Adherence, and Toxicity Escalation
7 Chapter 7: Symptom Management and Supportive Care
Symptom Assessment, Toxicity Grading, and Prioritization Hematologic, Immunologic, and Infection Supportive Care GI, GU, Nutrition, and Hydration Supportive Care Integumentary, Ostomy, Lymphedema, and Wound Care Respiratory, Cardiovascular, Neurologic, and Musculoskeletal Symptoms Pain Management, Pharmacologic, and Integrative Care Vascular Access Device Care and Supportive Care Coordination
8 Chapter 8: Oncologic Emergencies and Rapid Escalation
Sepsis, SIRS, Neutropenic Infection, and Shock Tumor Lysis, Hypercalcemia, SIADH, and Metabolic Emergencies Hypersensitivity, Anaphylaxis, and Infusion Reactions Spinal Cord Compression, SVC Syndrome, Increased ICP, and Obstructions DIC, VTE, Bleeding, and Thrombotic Emergencies Pneumonitis, Extravasation, and Local Therapy Emergencies Immune-Related Emergencies, CRS, ICANS, and Urgent Triage
9 Chapter 9: Psychosocial Dimensions of Oncology Care
Distress Screening, Emotional Response, and Crisis Care Cultural, Spiritual, Religious, and Language-Responsive Care Family, Caregiver Support, and Shared Decision-Making Sexuality, Fertility, Gender, and Body Image Concerns Learning Barriers, Health Literacy, and Patient Education Financial Toxicity, Support Systems, and Resource Referrals
10 Chapter 10: Mixed OCN Case Labs
New Diagnosis Navigation and Treatment Planning Case Lab Chemotherapy Infusion Reaction and Extravasation Case Lab Immunotherapy Toxicities and CRS ICANS Case Lab Radiation Surgery and Localized Therapy Case Lab Symptom Management Neutropenia Pain and Nutrition Case Lab Oncologic Emergency TLS SVC Cord Compression Case Lab Survivorship Palliative Psychosocial and Discharge Case Lab
11 Chapter 11: Final Review, High-Yield Tables, and OCN Exam-Day Readiness
Blueprint Quick Reference and Domain Triage High-Yield Oncology Safety and Emergency Tables Generic Drug Stems, Labs, and Supportive Care Patterns Final Week Practice Plan, Error Log, and Stamina Final 48 Hours, PSI Test Day, and Retake Planning
Screening, Early Detection, and High-Risk Referrals
Key Takeaways Explain This Topic AI
Screening is for asymptomatic people; any symptom or abnormal finding demands diagnostic evaluation, not routine screening.
OCN scenarios test correct escalation after red flags rather than memorization of every screening interval.
High-risk patients may need genetic counseling, earlier or supplemental screening, or specialized high-risk clinics.
Lung screening uses low-dose CT for ages 50-80 with a 20 pack-year history who currently smoke or quit within 15 years.
Abnormal results require closed-loop follow-up so patients are not lost between primary care, imaging, oncology, and specialty services.
Last updated: June 2026
- Screening, Early Detection, and High-Risk Referrals
- Screening versus diagnosis
Screening tests people without signs or symptoms to find precancerous change or early-stage disease. Diagnostic evaluation investigates a symptom, abnormal physical finding, or abnormal screening result. Many OCN items hinge on this single distinction. A patient with a palpable breast mass does not get reassurance that a routine mammogram is due next year; she needs prompt diagnostic imaging. New rectal bleeding is a symptom requiring evaluation, not a reminder about routine colorectal screening.
The exam also expects the nurse to distinguish primary, secondary, and tertiary prevention : primary prevention stops disease before it starts (HPV vaccination, tobacco cessation), secondary prevention detects disease early in asymptomatic people (screening mammography, colonoscopy, Pap testing), and tertiary prevention limits complications and disability in those already diagnosed (rehabilitation, late-effect surveillance). Screening is therefore a secondary-prevention activity, and confusing it with diagnostic workup is the most common trap in this content area.
Common adult screening themes
The nurse need not recite every national interval, but should know the major sites and rough average-risk benchmarks (which vary by guideline body such as the American Cancer Society [ACS] and US Preventive Services Task Force [USPSTF]):
- Cancer site Common average-risk approach
- Breast Mammography typically offered beginning around age 40-50, then periodically
- Cervix Cytology and/or HPV testing roughly ages 21/25 through 65
- Colorectal Begin at age 45 (colonoscopy, FIT, FIT-DNA, or others)
- Lung Annual low-dose CT, ages 50-80, 20 pack-year history, current or quit within 15 years
- Prostate Shared decision-making about PSA, generally starting around age 50
Screening may be inappropriate when limited life expectancy, frailty, or active advanced illness makes benefit unlikely; recognizing this is a frequent exam nuance. Screening also carries potential harms the nurse should be able to name: false positives that trigger anxiety and invasive workup, false negatives that falsely reassure, overdiagnosis of indolent disease that would never have caused harm, and radiation or procedural risk. A high sensitivity test minimizes false negatives (good for ruling disease out), while high specificity minimizes false positives.
These trade-offs explain why shared decision-making, not blanket testing, drives prostate and lung screening.
Early detection scenarios
A 55-year-old former smoker asking about lung screening needs a pack-year and quit-date assessment, symptom review, and confirmation he could tolerate curative treatment, then referral for shared decision-making and low-dose computed tomography (LDCT) if eligible. Pack-years are calculated as packs per day multiplied by years smoked, so one pack daily for 20 years equals 20 pack-years - exactly the LDCT threshold. A patient with cervical dysplasia who missed colposcopy follow-up needs navigation, not shame.
A survivor who received chest radiation before age 30 (e.g., for Hodgkin lymphoma) often needs earlier breast surveillance , frequently with magnetic resonance imaging (MRI) starting around 8-10 years after radiation or by age 25-30. A patient with long-standing ulcerative colitis or Crohn colitis needs gastroenterology-directed colon surveillance on a shorter interval than the average-risk population because chronic inflammation raises colorectal cancer risk.
High-risk referrals
Refer for hereditary cancer risk assessment when history suggests inherited susceptibility: ovarian cancer at any age, young-onset breast cancer, male breast cancer, pancreatic cancer with family history, triple-negative breast cancer under 60, medullary thyroid cancer, retinoblastoma, or a colon/endometrial cluster suggesting Lynch syndrome (mismatch repair deficiency) . Collect a three-generation pedigree with ages at diagnosis, lineage, and ancestry (e.g., Ashkenazi Jewish heritage raises BRCA1/2 probability), but never delay referral for a concerning pattern.
The nurse should generally not order germline genetic testing independently; the OCN-correct step is referral to a genetic counselor or high-risk clinic who can obtain informed consent, select the right panel, and interpret results, including variants of uncertain significance. High-risk patients may then qualify for earlier or supplemental surveillance, risk-reducing medication, or risk-reducing surgery, decisions that belong with specialists rather than at the bedside.
Red flags that override routine screening
The following symptoms require diagnostic workup, not screening reassurance:
- Unexplained weight loss, drenching night sweats, persistent fever
- Postmenopausal bleeding, new breast mass, nipple discharge
- Hemoptysis, persistent hoarseness, dysphagia, persistent cough
- Change in bowel habits, rectal bleeding, painless jaundice
- Persistent focal bone pain, new neurologic deficit, enlarging lymph node, nonhealing lesion
In exam scenarios, the safest answer recognizes the red flag and escalates; education alone is insufficient when a finding suggests possible cancer or recurrence.
Reducing barriers and closing the loop
Many missed screenings reflect structural barriers , not low motivation. Assess transportation, time off work, insurance, immigration concerns, disability access, language, prior trauma, and mistrust. Interventions include interpreter services, patient navigation, same-day scheduling, reminder systems, financial counseling, and mobile units. Teaching should be plain-language and specific: what the test detects, what preparation it needs, what the result could mean, and exactly how and when results will be communicated.
Screening improves outcomes only when abnormal findings travel through to diagnosis: confirm who owns the next step, when it is scheduled, what preparation is needed, and how results are communicated. Documentation should capture education, the referral placed, barriers identified, and the patient's decision, including any informed refusal. If a patient repeatedly misses follow-up, explore barriers rather than labeling them noncompliant - a missed appointment is a clinical signal, not a character judgment, and the nurse's job is to remove the obstacle and reschedule promptly.